focus -WSS

focus

author：Wikipedia 2025-09-30 15:15:37 - browse：84

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： 5 shark bites reported on Long Island as officials deploy surveillance drones

WSS

Man pleads guilty to raping Ohio girl who ended up traveling across state lines for abortion

EU moves toward latest gene techniques in food production to counter climate change, shortages

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

Dark money group runs ads on China biotech bill

China dismisses criticism of top diplomat's comments appearing to push for race

Search warrant issued in 1996 disappearance of Kristin Smart

Wikipedia

focus

explore

Continuity nursing helped my family in our darkest PICU moments

David Sabatini, ex

How one medical school became remarkably diverse

The leaders of Italy and Poland say European Union should focus on stopping migration

In age of alternative facts, a scholarly course on calling out crap

A bus careens into a gulch in southern Mexico, leaving 27 people dead

Apple is now the first public company to be valued at $3 trillion

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Jerome Adams on the need for new antivirals for Covid

Latest bird flu infection made farmworker sicker than earlier cases

hotspot

First Opinion Podcast: What happens when kids become caregivers?

Princess Kate attends Wimbledon with Roger Federer: See the photos

Lab trade group sues FDA to halt regulation of lab

Adam's Biotech Scorecard: Do Sarepta's exon

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Startling documents reveal new facets of Sacklers' opioid empire

leisure time

focus

entertainment

leisure time